Treatment Information

Back

Mesothelioma treatment details. Immunotherapy.

St. Bartholomew's Hospital, London, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:2City/State/Province:London
Treatments:ImmunotherapyHospital:St. Bartholomew's Hospital
Drugs:Journal:Link
Date:Jan 2001

Description:

Patients: This Phase II study involved 29 patients with malignant pleural mesothelioma. None of these patients had been administered previous chemotherapy or immunotherapy.

Treatment: The treatment consisted of the administration of human recombinant Interleukin-2.

Toxicity: Toxicities included fever (grade 2), cutaneous toxicity, nausea and vomiting (grade 1), and chest pains.

Results: Overall median survival was 9 months from the date of first treatment.

Support: The cost of the interleukin-2 was subsidized by Chiron UK Limited. Chiron manufactures interleukin-2 (Proleukin).

Correspondence: R.M. Rudd, MD





Back